Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature
Giacomo Caldarola, Federico Pirrò, Alessandro Di Stefani, et al.
Expert Opinion on Biological Therapy (2020) Vol. 20, Iss. 6, pp. 665-672
Closed Access | Times Cited: 70

Showing 1-25 of 70 citing articles:

Psoriasis
C.E.M. Griffiths, April W. Armstrong, Jóhann E. Guðjónsson, et al.
The Lancet (2021) Vol. 397, Iss. 10281, pp. 1301-1315
Closed Access | Times Cited: 1461
The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside
Taoming Liu, Sheng Li, Shuni Ying, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 228
Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases
Anna Kychygina, Myriam Cassagne, M. Tauber, et al.
Clinical Reviews in Allergy & Immunology (2022) Vol. 62, Iss. 3, pp. 519-533
Closed Access | Times Cited: 51
Assessment of safety profile of secukinumab in real-world scenario using United States food and drug administration adverse event reporting system database
Vishnu Eshwar, Ashwin Kamath
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 12
TWEAK functions with TNF and IL-17 on keratinocytes and is a potential target for psoriasis therapy
Rinkesh Kumar Gupta, Donald T. Gracias, Daniela Salgado Figueroa, et al.
Science Immunology (2021) Vol. 6, Iss. 65
Open Access | Times Cited: 55
So close, and yet so far away: The dichotomy of the specific immune response and inflammation in psoriasis and atopic dermatitis
Alexander Schäbitz, Kilian Eyerich, Natalie Garzorz‐Stark
Journal of Internal Medicine (2021) Vol. 290, Iss. 1, pp. 27-39
Open Access | Times Cited: 36
Pathogenesis of Paradoxical Reactions Associated with Targeted Biologic Agents for Inflammatory Skin Diseases
Fumi Miyagawa
Biomedicines (2022) Vol. 10, Iss. 7, pp. 1485-1485
Open Access | Times Cited: 26
The immunoregulatory effects of natural products on psoriasis via its action on Th17 cells versus regulatory T cells balance
Lingyuan Zhong, Nan Luo, Xiaojing Zhong, et al.
International Immunopharmacology (2022) Vol. 110, pp. 109032-109032
Open Access | Times Cited: 25
From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment
Sílvia Vidal, L. Puig, José-Manuel Carrascosa-Carrillo, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 13, pp. 6740-6740
Open Access | Times Cited: 25
Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy
Marco Galluzzo, Giacomo Caldarola, Clara De Simone, et al.
Expert Opinion on Biological Therapy (2021) Vol. 21, Iss. 9, pp. 1299-1310
Open Access | Times Cited: 24
Eczematous drug eruption in patients with psoriasis under anti‐interleukin‐17A: does interleukin‐22 play a key role?
Matteo Megna, Giuseppina Caiazzo, Melania Parisi, et al.
Clinical and Experimental Dermatology (2021) Vol. 47, Iss. 5, pp. 918-925
Closed Access | Times Cited: 24
Eczematoid paradoxical reaction in psoriasis patients following secukinumab
Heng Zhang, Yan Zhao, Lingxia Wang, et al.
Chinese Medical Journal (2025)
Open Access
Targeting nail psoriasis: IL-17A inhibitors demonstrate site-specific superiority over IL-23 inhibitor in a 24-week dermoscopy-guided real-world cohort
Yan Xia, Minglan Shi, Bin Wang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Ustekinumab is effective in the treatment of linear psoriasis: a case report and literature review
Jinxu Qi, Qing Zhu, Mengdi Feng, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
RNA-Seq Identifies Marked Th17 Cell Activation and Altered CFTR Expression in Different Atopic Dermatitis Subtypes in Chinese Han Populations
Xin Tian, Baoyi Liu, Lijie Chen, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 21
Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study
Giacomo Caldarola, Andrea Chiricozzi, Matteo Megna, et al.
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 4, pp. 365-370
Closed Access | Times Cited: 9
Ixekizumab-induced urticaria is associated with the short duration of remission in psoriasis by activation of mast cells
Li Zhang, Xia Li, Xintian Xu, et al.
Journal of the American Academy of Dermatology (2024) Vol. 90, Iss. 5, pp. 970-976
Open Access | Times Cited: 3
Paradoxical psoriasis induced by IL-17 antagonists
Yachen Wang, Fengling Yang, Ruizhe Wang, et al.
Indian Journal of Dermatology Venereology and Leprology (2024) Vol. 90, pp. 623-631
Open Access | Times Cited: 3
Long-Term Effectiveness of Brodalumab for the Treatment of Moderate-To-Severe Psoriasis: A Real-Life Multicenter Study of Up to 3 Years in a Real-Life Italian Cohort
Giacomo Caldarola, Marco Galluzzo, Nicoletta Bernardini, et al.
Dermatology Practical & Conceptual (2024) Vol. 14, Iss. 2, pp. e2024152-e2024152
Open Access | Times Cited: 3
Dysbiosis of the human skin mycobiome in patients receiving systemic IL-23 inhibitors
Yuta Koike, Sayaka Kuwatsuka, Daisuke Motooka, et al.
Allergology International (2024)
Open Access | Times Cited: 3
Development of a clinical algorithm to predict phenotypic switches between atopic dermatitis and psoriasis (the “Flip‐Flop” phenomenon)
Svenja Müller, Thomas Welchowski, Matthias Schmid, et al.
Allergy (2023) Vol. 79, Iss. 1, pp. 164-173
Open Access | Times Cited: 8
Eczematous Drug Eruptions
Amy E. Blum, Susan Burgin
American Journal of Clinical Dermatology (2021) Vol. 22, Iss. 3, pp. 349-366
Closed Access | Times Cited: 18
Predictive factors of atopic‐like dermatitis induced by IL‐17A inhibitors in patients with psoriasis: A 2‐year follow‐up study
Xin Tang, Qian Li, Ying Zhou, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 12, pp. 2509-2516
Closed Access | Times Cited: 7
Long-term efficacy, safety, and drug survival of secukinumab in patients with psoriasis in Turkey: a retrospective analysis of real-world experience
Fatma Elif Yıldırım, Fatma Aslı Hapa
Advances in Dermatology and Allergology (2024) Vol. 41, Iss. 1, pp. 49-55
Open Access | Times Cited: 2
Anti-IL-17 monoclonal antibodies and bullous pemphigoid: treatment or causal agents? A case series and review of the literature
Anna Paola Lugli, Giacomo Caldarola, Gennaro Marco Falco, et al.
Drugs in Context (2024) Vol. 13, pp. 1-6
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top